{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:32:22Z","timestamp":1794270742836,"version":"4.9.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8056","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Neoantigen vaccines are under investigation for various cancers, including epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>)-driven lung cancers<jats:sup>1,2<\/jats:sup>. We tracked the phylogenetic history of an <jats:italic>EGFR<\/jats:italic> mutant lung cancer treated with erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine (NPV) targeting ten somatic mutations, including <jats:italic>EGFR<\/jats:italic> exon 19 deletion (ex19del). The ex19del mutation was clonal, but is likely to have appeared after a whole-genome doubling (WGD) event. Following osimertinib and NPV treatment, loss of the ex19del mutation was identified in a progressing small-cell-transformed liver metastasis. Circulating tumour DNA analyses tracking 467 somatic variants revealed the presence of this <jats:italic>EGFR<\/jats:italic> wild-type clone before vaccination and its expansion during osimertinib\/NPV therapy. Despite systemic T cell reactivity to the vaccine-targeted ex19del neoantigen, the NPV failed to halt disease progression. The liver metastasis lost vaccine-targeted neoantigens through chromosomal instability and exhibited a hostile microenvironment, characterized by limited immune infiltration, low <jats:italic>CXCL9<\/jats:italic> and elevated M2 macrophage levels. Neoantigens arising post-WGD were more likely to be absent in the progressing liver metastasis than those occurring pre-WGD, suggesting that prioritizing pre-WGD neoantigens may improve vaccine design. Data from the TRACERx 421 cohort<jats:sup>3<\/jats:sup> provide evidence that pre-WGD mutations better represent clonal variants, and owing to their presence at multiple copy numbers, are less likely to be lost in metastatic transition. These data highlight the power of phylogenetic disease tracking and functional T cell profiling to understand mechanisms of immune escape during combination therapies.<\/jats:p>","DOI":"10.1038\/s41586-025-08586-y","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:03:36Z","timestamp":1739981016000},"page":"1052-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Clonal driver neoantigen loss under EGFR TKI and immune selection pressures"],"prefix":"10.1038","volume":"639","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-8332","authenticated-orcid":false,"given":"Maise","family":"Al Bakir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-978X","authenticated-orcid":false,"given":"James L.","family":"Reading","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Przewrocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7071-7889","authenticated-orcid":false,"given":"Amber","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yien Ning Sophia","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie K.","family":"Bentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraju","family":"Veeriah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-5279","authenticated-orcid":false,"given":"Sophia","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Garnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kalavakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4817-0565","authenticated-orcid":false,"given":"Carlos","family":"Mart\u00ednez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3022-8737","authenticated-orcid":false,"given":"Clare","family":"Puttick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4999","authenticated-orcid":false,"given":"Ariana","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3347-562X","authenticated-orcid":false,"given":"Daniel E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-1312","authenticated-orcid":false,"given":"David A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Abbosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crispin T.","family":"Hiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-0307","authenticated-orcid":false,"given":"Cristina","family":"Naceur-Lombardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B. K.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Petkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland F.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8417-1891","authenticated-orcid":false,"given":"Felipe","family":"G\u00e1lvez-Cancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-0914","authenticated-orcid":false,"given":"Kevin","family":"Litchfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-4463","authenticated-orcid":false,"given":"Peter","family":"Meldgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-8099","authenticated-orcid":false,"given":"Boe Sandahl","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Bille","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Domingo-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy I. M.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-191X","authenticated-orcid":false,"given":"Mohammad","family":"Kadivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-4344","authenticated-orcid":false,"given":"Sine Reker","family":"Hadrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7417-3970","authenticated-orcid":false,"given":"Benny","family":"Chain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-1700","authenticated-orcid":false,"given":"Sergio A.","family":"Quezada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9537-4045","authenticated-orcid":false,"given":"Nicholas","family":"McGranahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"8586_CR1","doi-asserted-by":"publisher","first-page":"e002531","DOI":"10.1136\/jitc-2021-002531","volume":"9","author":"F Li","year":"2021","unstructured":"Li, F. et al. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J. Immunother. Cancer 9, e002531 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"8586_CR2","doi-asserted-by":"publisher","first-page":"1022598","DOI":"10.3389\/fimmu.2022.1022598","volume":"13","author":"J Lin","year":"2022","unstructured":"Lin, J. et al. An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. Front. Immunol. 13, 1022598 (2022).","journal-title":"Front. Immunol."},{"key":"8586_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525\u2013533 (2023).","journal-title":"Nature"},{"key":"8586_CR4","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M. & Paz-Ares, L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann. Oncol. 29, i10\u2013i19 (2018).","journal-title":"Ann. Oncol."},{"key":"8586_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02584-z","volume":"9","author":"R Nahar","year":"2018","unstructured":"Nahar, R. et al. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nat. Commun. 9, 216 (2018).","journal-title":"Nat. Commun."},{"key":"8586_CR6","doi-asserted-by":"publisher","first-page":"e000060","DOI":"10.1136\/esmoopen-2016-000060","volume":"1","author":"F Morgillo","year":"2016","unstructured":"Morgillo, F., Della Corte, C. M., Fasano, M. & Ciardiello, F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open 1, e000060 (2016).","journal-title":"ESMO Open"},{"key":"8586_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.21037\/tlcr.2020.01.10","volume":"9","author":"L Liu","year":"2020","unstructured":"Liu, L., Lizaso, A., Mao, X., Yang, N. & Zhang, Y. Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report. Transl. Lung Cancer Res. 9, 144\u2013147 (2020).","journal-title":"Transl. Lung Cancer Res."},{"key":"8586_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/cas.12905","volume":"107","author":"H Mizuuchi","year":"2016","unstructured":"Mizuuchi, H. et al. Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Cancer Sci. 107, 461\u2013468 (2016).","journal-title":"Cancer Sci."},{"key":"8586_CR9","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","volume":"10","author":"TM Kim","year":"2015","unstructured":"Kim, T. M. et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J. Thorac. Oncol. 10, 1736\u20131744 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"8586_CR10","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288\u20132301 (2018).","journal-title":"N. Engl. J. Med."},{"key":"8586_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.21037\/tlcr.2019.06.02","volume":"8","author":"D Bruno","year":"2019","unstructured":"Bruno, D. & Dowlati, A. Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how? Transl. Lung Cancer Res. 8, 710\u2013714 (2019).","journal-title":"Transl. Lung Cancer Res."},{"key":"8586_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14273-0","volume":"11","author":"A Reuben","year":"2020","unstructured":"Reuben, A. et al. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat. Commun. 11, 603 (2020).","journal-title":"Nat. Commun."},{"key":"8586_CR13","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.21037\/jtd.2020.03.118","volume":"12","author":"S Zhong","year":"2020","unstructured":"Zhong, S., Cui, Y., Liu, Q. & Chen, S. CAR-T cell therapy for lung cancer: a promising but challenging future. J. Thorac. Dis. 12, 4516\u20134521 (2020).","journal-title":"J. Thorac. Dis."},{"key":"8586_CR14","doi-asserted-by":"crossref","unstructured":"Young, K., Lu, Z. & Qian, W. The Novel Engineering Strategies and Clinical Progress of Solid Tumor in CAR-T Cell Therapy (Frontiers Media SA, 2022).","DOI":"10.3389\/978-2-88976-791-5"},{"key":"8586_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019).","journal-title":"Front. Immunol."},{"key":"8586_CR16","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"8586_CR17","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","volume":"16","author":"MG Oser","year":"2015","unstructured":"Oser, M. G., Niederst, M. J., Sequist, L. V. & Engelman, J. A. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 16, e165\u2013e172 (2015).","journal-title":"Lancet Oncol."},{"key":"8586_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7377","volume":"6","author":"MJ Niederst","year":"2015","unstructured":"Niederst, M. J. et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun. 6, 6377 (2015).","journal-title":"Nat. Commun."},{"key":"8586_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 121, 725\u2013737 (2019).","journal-title":"Br. J. Cancer"},{"key":"8586_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"8586_CR21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1080\/10428194.2017.1330955","volume":"59","author":"T Danielzik","year":"2018","unstructured":"Danielzik, T. et al. Sensitive detection of rare antigen-specific T cells directed against Wilms\u2019 tumor 1 by FluoroSpot assay. Leuk. Lymphoma 59, 490\u2013492 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"8586_CR22","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","volume":"23","author":"M Scurr","year":"2017","unstructured":"Scurr, M. et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin. Cancer Res. 23, 6771\u20136780 (2017).","journal-title":"Clin. Cancer Res."},{"key":"8586_CR23","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/2326-6066.CIR-18-0129","volume":"6","author":"L Danilova","year":"2018","unstructured":"Danilova, L. et al. The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunol. Res. 6, 888\u2013899 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"8586_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.immuni.2021.02.014","volume":"54","author":"S-H Chiou","year":"2021","unstructured":"Chiou, S.-H. et al. Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity 54, 586\u2013602.e8 (2021).","journal-title":"Immunity"},{"key":"8586_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"8586_CR26","doi-asserted-by":"publisher","first-page":"e138740","DOI":"10.1172\/JCI138740","volume":"131","author":"C Lhuillier","year":"2021","unstructured":"Lhuillier, C. et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J. Clin. Invest. 131, e138740 (2021).","journal-title":"J. Clin. Invest."},{"key":"8586_CR27","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271.e11 (2017).","journal-title":"Cell"},{"key":"8586_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry, S. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv. Anat. Pathol. 24, 311\u2013335 (2017).","journal-title":"Adv. Anat. Pathol."},{"key":"8586_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","volume":"5","author":"P Danaher","year":"2017","unstructured":"Danaher, P. et al. Gene expression markers of tumor infiltrating leukocytes. J. Immunother. Cancer 5, 18 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"8586_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"8586_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614.e14 (2021).","journal-title":"Cell"},{"key":"8586_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152\u2013164 (2021).","journal-title":"Nat. Med."},{"key":"8586_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","volume":"616","author":"M Al Bakir","year":"2023","unstructured":"Al Bakir, M. et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature 616, 534\u2013542 (2023).","journal-title":"Nature"},{"key":"8586_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41586-023-05706-4","volume":"616","author":"C Mart\u00ednez-Ruiz","year":"2023","unstructured":"Mart\u00ednez-Ruiz, C. et al. Genomic\u2013transcriptomic evolution in lung cancer and metastasis. Nature 616, 543\u2013552 (2023).","journal-title":"Nature"},{"key":"8586_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"8586_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41592-020-01013-2","volume":"18","author":"M Tarabichi","year":"2021","unstructured":"Tarabichi, M. et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat. Methods 18, 144\u2013155 (2021).","journal-title":"Nat. Methods"},{"key":"8586_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613\u2013628 (2017).","journal-title":"Cell"},{"key":"8586_CR38","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109\u20132121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"8586_CR39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","volume":"29","author":"N Niknafs","year":"2023","unstructured":"Niknafs, N. et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat. Med. 29, 440\u2013449 (2023).","journal-title":"Nat. Med."},{"key":"8586_CR40","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"8586_CR41","doi-asserted-by":"publisher","first-page":"e153688","DOI":"10.1172\/jci.insight.153688","volume":"7","author":"H Asimgil","year":"2022","unstructured":"Asimgil, H. et al. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 7, e153688 (2022).","journal-title":"JCI Insight"},{"key":"8586_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.21037\/tlcr.2018.05.06","volume":"7","author":"PM de Groot","year":"2018","unstructured":"de Groot, P. M., Wu, C. C., Carter, B. W. & Munden, R. F. The epidemiology of lung cancer. Transl. Lung Cancer Res. 7, 220\u2013233 (2018).","journal-title":"Transl. Lung Cancer Res."},{"key":"8586_CR43","doi-asserted-by":"publisher","first-page":"e41017","DOI":"10.1371\/journal.pone.0041017","volume":"7","author":"K Tabara","year":"2012","unstructured":"Tabara, K. et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE 7, e41017 (2012).","journal-title":"PLoS ONE"},{"key":"8586_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav3937","volume":"5","author":"E Sugiyama","year":"2020","unstructured":"Sugiyama, E. et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non\u2013small cell lung cancer. Sci. Immunol. 5, eaav3937 (2020).","journal-title":"Sci. Immunol."},{"key":"8586_CR45","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3389\/fimmu.2020.01366","volume":"11","author":"D Wu","year":"2020","unstructured":"Wu, D. et al. Identification of clonal neoantigens derived from driver mutations in an EGFR-mutated lung cancer patient benefitting from anti-PD-1. Front. Immunol. 11, 1366 (2020).","journal-title":"Front. Immunol."},{"key":"8586_CR46","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"8586_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44, e108 (2016).","journal-title":"Nucleic Acids Res."},{"key":"8586_CR48","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.pex-2158\/v1","author":"K Grigoriadis","year":"2023","unstructured":"Grigoriadis, K. et al. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.pex-2158\/v1 (2023).","journal-title":"Res. Sq."},{"key":"8586_CR49","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"8586_CR50","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, V. A. et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat. Commun. 8, 1324 (2017).","journal-title":"Nat. Commun."},{"key":"8586_CR51","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","volume":"25","author":"K Joshi","year":"2019","unstructured":"Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 25, 1549\u20131559 (2019).","journal-title":"Nat. Med."},{"key":"8586_CR52","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3389\/fimmu.2017.01267","volume":"8","author":"T Oakes","year":"2017","unstructured":"Oakes, T. et al. Quantitative characterization of the T cell receptor repertoire of na\u00efve and memory subsets using an integrated experimental and computational pipeline which is robust, economical, and versatile. Front. Immunol. 8, 1267 (2017).","journal-title":"Front. Immunol."},{"key":"8586_CR53","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41587-020-0505-4","volume":"38","author":"H Huang","year":"2020","unstructured":"Huang, H., Wang, C., Rubelt, F., Scriba, T. J. & Davis, M. M. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat. Biotechnol. 38, 1194\u20131202 (2020).","journal-title":"Nat. Biotechnol."},{"key":"8586_CR54","doi-asserted-by":"publisher","unstructured":"Al Bakir, M. et al. Clonal driver neoantigen loss under EGFR TKI and immune selection pressures. Zenodo https:\/\/doi.org\/10.5281\/zenodo.14028323 (2025).","DOI":"10.5281\/zenodo.14028323"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08586-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T07:36:43Z","timestamp":1743320203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-08586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":54,"journal-issue":{"issue":"8056","published-print":{"date-parts":[[2025,3,27]]}},"alternative-id":["8586"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-08586-y","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.B. has consulted for Achilles Therapeutics. J.L.R. reports speaker fees from Boehringer Ingelheim and GlaxoSmithKline and consults for Achilles Therapeutics Ltd. J.L.R. and has filed patents for cancer early detection (PCT\/EP2023\/076521 and PCT\/EP2023\/076511) using systemic TCR-seq data, on which S.G. is a co-inventor. A.T.G. and P.K. are former or current employees of Invitae or ArcherDx and report stock ownership. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda; consultancy fees from AstraZeneca, Thermo Fisher Scientific, Takeda, Amgen, Janssen, MIM Software, Bristol Myers Squibb (BMS) and Eli Lilly; and has received educational support from Takeda and Amgen. C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS; has patents issued to detect tumour recurrence (PCT\/GB2017\/053289) and for methods for lung cancer detection (PCT\/US2017\/028013) and is co-inventor to a patent application to determine methods and systems for tumour monitoring (PCT\/EP2022\/077987); and is a current employee of AstraZeneca. C.T.H. has received speaker fees from AstraZeneca. K.L. has a patent on indel burden and CPI response pending and outside of the submitted work, speaker fees from Roche tissue diagnostics, research funding from CRUK TDL\/Ono\/LifeArc alliance and Genesis Therapeutics, and consulting roles with Monopteros Therapeutics and Kynos Therapeutics, all outside of the submitted work. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, Bristol Myers Squibb, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. T.A. reports employment and stock options with Ellipses Pharma, and is an advisory board member for Engitix, iOnctura, Labgenius and Further Group. S.R.H. is the co-inventor of the patents WO2015185067 and WO2015188839 for the barcoded MHC technology which is licenced to Immudex and co-inventor of the licensed patent for Combinatorial encoding of MHC multimers (EP2088\/009356), licensee: Sanquin, NL. S.A.Q. is a co-founder, stockholder and Chief Scientific Officer of Achilles Therapeutics. S.V. is a co-inventor to a patent of methods for detecting molecules in a sample (patent no. 10,578,620). N.M. has stock options in and has consulted for Achilles Therapeutics and holds a European patent in determining HLA LOH (PCT\/GB2018\/052004), and is a co-inventor to a patent to identifying responders to cancer treatment (PCT\/GB2018\/051912). C.S. acknowledges grant support from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae (previously ArcherDx Inc.\u2014collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical. He is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL\u2019s Scientific Advisory Board. He receives consultant fees from Achilles Therapeutics (also SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre\u2013Shanghai, Metabomed (until July 2022) and the Sarah Cannon Research Institute; had stock options in Apogen Biotechnologies and GRAIL until June 2021 and at present has stock options in Epic Bioscience and Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. holds patents relating to assay technology to detect tumour recurrence (PCT\/GB2017\/053289), targeting neoantigens (PCT\/EP2016\/059401), identifying patent response to immune checkpoint blockade (PCT\/EP2016\/071471), determining HLA LOH (PCT\/GB2018\/052004), predicting survival rates of patients with cancer (PCT\/GB2020\/050221), identifying patients who respond to cancer treatment (PCT\/GB2018\/051912), US patent relating to detecting tumour mutations (PCT\/US2017\/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion\/deletion mutation targets (PCT\/GB2018\/051892), and is co-inventor to a patent application to determine methods and systems for tumour monitoring (PCT\/EP2022\/077987).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}